APPENDICES. A systematic review and economic model of the ...
APPENDICES. A systematic review and economic model of the ...
APPENDICES. A systematic review and economic model of the ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
340<br />
Appendix 12<br />
Study Intervention Participants Outcomes<br />
Core symptoms<br />
ADHD Rating Scale total score<br />
CPRS-S (short form)<br />
ADHD Rating Scale subscales<br />
(inattentive; hyperactive/impulsive)<br />
Reference<br />
Spencer et al., 2002 89<br />
Source<br />
Updated search<br />
Co-existent problems<br />
Not reported<br />
Inclusion criteria<br />
1. Diagnosis <strong>of</strong> ADHD<br />
2. Score on ADHD Rating Scale <strong>of</strong> >1.5 SD above age <strong>and</strong> gender<br />
norms for <strong>the</strong>ir diagnostic subtype (primarily inattentive or primarily<br />
hyperactive/impulsive) or <strong>the</strong> total score for <strong>the</strong> combined subtype<br />
3. No poor metabolisers <strong>of</strong> CYP2D6<br />
4. Weight >2 kg at study entry<br />
5. No documented history <strong>of</strong> bipolar I or II disorder or any history <strong>of</strong><br />
psychosis<br />
6. No history <strong>of</strong> organic brain disease or history <strong>of</strong> seizure disorder<br />
7. No psychotropic medication<br />
8. No history <strong>of</strong> alcohol or drug abuse within past 3 months <strong>and</strong> on<br />
significant prior or current medical conditions<br />
9. Age 7–13 years<br />
10. Normal intelligence on WISC<br />
Arm 1<br />
ATX<br />
Maximum dose 2 mg/kg/day<br />
(90 mg/day) in two or three daily<br />
doses depending on prior<br />
psychostimulant exposure<br />
(Individual administering medication<br />
not reported)<br />
Setting<br />
USA<br />
Educational performance<br />
Not reported<br />
Design<br />
Parallel trial<br />
Psychological function<br />
Not reported<br />
Arm 2<br />
Placebo<br />
(Individual administering medication<br />
not reported)<br />
Depression or anxiety<br />
Not reported<br />
Quality <strong>of</strong> life<br />
CGI–ADHD, severity<br />
Diagnostic criteria<br />
DSM-IV<br />
Duration<br />
12 weeks<br />
Purpose<br />
To assess <strong>the</strong> safety <strong>and</strong><br />
efficacy <strong>of</strong> ATX<br />
compared with placebo<br />
in school-aged children<br />
with ADHD<br />
Adverse events<br />
Unsolicited adverse events<br />
Additional outcomes<br />
Not reported<br />
Number<br />
Total r<strong>and</strong>omised = 144<br />
Arm 1 = 64<br />
Arm 2 = 62<br />
Total withdrawals = 34<br />
Arm 1 = 17<br />
Arm 2 = 17<br />
(For both trials: ATX n = 129, placebo n = 124)<br />
Males: ATX n = 98, placebo n = 103<br />
Females: ATX n = 31, placebo n = 21<br />
Reasons for withdrawals:<br />
The most common reason for discontinuation was lack <strong>of</strong> efficacy<br />
R<strong>and</strong>omisation procedure:<br />
Patients were stratified according to prior exposure to psychostimulants.<br />
20 patients with no prior exposure to psychostimulants were<br />
r<strong>and</strong>omised to MPH. MPH treatment was included to validate study<br />
design in <strong>the</strong> event that ATX failed to separate from placebo. MPH<br />
results not reported<br />
continued